Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1512409
Disease: Hepatocarcinogenesis
Hepatocarcinogenesis
0.020 PosttranslationalModification disease BEFREE 5'CpG islands methylation of p16 and p15 genes might be an early event in hepatocarcinogenesis. 15112341 2004
CUI: C4020732
Disease: Mitochondrial abnormalities
Mitochondrial abnormalities
0.010 GeneticVariation disease BEFREE Mitochondrial abnormalities in the pre-synaptic motor nerve terminals are detected at postnatal day 6, which are more pronounced at P15 and accompanied by a loss of synaptic vesicles and synaptophysin protein coupled with NMJs of a smaller size at a time when there is no detectable motor neuron loss. 29194538 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE A novel compound, ferulic acid-bound resveratrol, induces the tumor suppressor gene p15 and inhibits the three-dimensional proliferation of colorectal cancer cells. 31440879 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.040 GeneticVariation disease BEFREE A panel of human carcinomas of the exocrine pancreas orthotopically implanted and perpetuated in nude mice and pancreatic cancer cell lines were studied. p15 gene alterations, mainly homozygous deletions that involved exons 1 and/or 2, were found in the 62.5% (5 of 8) of pancreatic xenografts whereas Smad4 gene aberrations were found in one of eight xenografts and in two of seven cell lines. 9788440 1998
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas
0.040 GeneticVariation disease BEFREE A panel of human carcinomas of the exocrine pancreas orthotopically implanted and perpetuated in nude mice and pancreatic cancer cell lines were studied. p15 gene alterations, mainly homozygous deletions that involved exons 1 and/or 2, were found in the 62.5% (5 of 8) of pancreatic xenografts whereas Smad4 gene aberrations were found in one of eight xenografts and in two of seven cell lines. 9788440 1998
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.020 GeneticVariation disease BEFREE A previous analysis of these NSCLC samples for p16 gene alterations revealed that the three cases with homozygous deletions of the p15 gene also have homozygous deletions of the p16 gene. 8519415 1995
Human immunodeficiency virus (HIV) II infection category B1
0.020 GeneticVariation disease BEFREE A segment of the gag gene of the human immunodeficiency virus (HIV) (HTLV-IIIB strain), the virus which causes acquired immunodeficiency syndrome (AIDS), has been cloned into the bacterial expression vector, pCQV2, and mapped to the right-hand portion of the gag gene containing the carboxyl-terminal portion of p24 and the amino-terminal portion of p15. 2449245 1988
CUI: C0001175
Disease: Acquired Immunodeficiency Syndrome
Acquired Immunodeficiency Syndrome
0.010 AlteredExpression group BEFREE A segment of the gag gene of the human immunodeficiency virus (HIV) (HTLV-IIIB strain), the virus which causes acquired immunodeficiency syndrome (AIDS), has been cloned into the bacterial expression vector, pCQV2, and mapped to the right-hand portion of the gag gene containing the carboxyl-terminal portion of p24 and the amino-terminal portion of p15. 2449245 1988
CUI: C0234535
Disease: Clonic Seizures
Clonic Seizures
0.010 Biomarker disease BEFREE A seizure rechallenge with flurothyl 7 days following TMDT exposure demonstrated longer latencies to the first clonic seizure but a faster progression into the tonic-clonic seizure in P15 and adult survivors as compared to their vehicle-injected counterparts. 29411537 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 GeneticVariation group BEFREE A statistically significant association between p16 gene alteration and bladder tumors of low stage (P < .01) and grade (P < .01) was observed; a significant association between p15 gene alteration and tumors of low stage (P < .01) was also detected. 7563186 1995
CUI: C0025202
Disease: melanoma
melanoma
0.090 AlteredExpression disease BEFREE A two-sided t-test was used to evaluate between-group differences in mean H scores and qΔCt values. p15 Expression was significantly increased in melanocytic nevi compared with melanomas (mean H scores, 254.8 versus 132.3; P < 0.001). 27855847 2016
CUI: C0085669
Disease: Acute leukemia
Acute leukemia
0.090 PosttranslationalModification disease BEFREE Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. 10706859 2000
Therapy-related myelodysplastic syndrome
0.010 PosttranslationalModification disease BEFREE Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. 12648079 2003
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute
0.100 PosttranslationalModification disease BEFREE Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. 12648079 2003
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.020 Biomarker disease BEFREE Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. 15978938 2005
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 AlteredExpression group BEFREE Aberrant hypermethylation was observed in 7 (32%) and 5 (23%) cases accompanied, by immunohistochemical loss of expression for p16 and p15 genes respectively, in both high stage and grade tumors from patients living in radiocontaminated areas, this being especially outstanding for the p16 gene. 12218456 2002
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.040 Biomarker disease BEFREE Aberrant methylation in the sample of patients with CLL was shown for secreted frizzled-related protein 1 (68.8%), secreted frizzled-related protein 2 (65.6%), death-associated protein kinase 1 (50.0%), E-cadherin (21.9%), secreted frizzled-related protein 4 (15.6%), p15 (9.4%), p16 (6.3%), retinoic acid receptor beta2 (3.1%), secreted frizzled-related protein 5 (3.1%) and tissue inhibitor of matrix metalloproteinases 3 (3.1%). 19347729 2009
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.070 PosttranslationalModification disease BEFREE Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis. 24908414 2014
CUI: C0004114
Disease: Astrocytoma
Astrocytoma
0.030 Biomarker disease BEFREE Abnormalities in the p16, p15 and CDK4 genes that regulate transition through the G1 phase of the cell cycle have been implicated in the malignant progression of astrocytomas. 8760309 1996
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE Abnormalities of tumor suppressor genes P16 and P15 in primary maxillofacial squamous cell carcinomas. 10432931 1999
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma
0.030 Biomarker disease BEFREE Abnormalities of tumor suppressor genes P16 and P15 in primary maxillofacial squamous cell carcinomas. 10432931 1999
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.030 GeneticVariation group BEFREE Acute/lymphomatous ATLL has frequent alterations of p15 (20%) and p16 (28-67%), while chronic/smoldering ATLL has fewer abnormalities of p15 (0-13%) and p16 (5-26%). 12040438 2002
CUI: C0023493
Disease: Adult T-Cell Lymphoma/Leukemia
Adult T-Cell Lymphoma/Leukemia
0.030 Biomarker disease BEFREE Acute/lymphomatous ATLL has frequent alterations of p15 (20%) and p16 (28-67%), while chronic/smoldering ATLL has fewer abnormalities of p15 (0-13%) and p16 (5-26%). 12040438 2002
CUI: C0017638
Disease: Glioma
Glioma
0.010 AlteredExpression disease BEFREE After infection, high levels of p16 and p15 were observed in two human glioma cell lines (U251 MG and U373 MG). 10939591 2000
CUI: C0037763
Disease: Spasm
Spasm
0.010 Biomarker phenotype BEFREE All doses of ACTH (range 0.02-1.0 mg/kg s.c.) and all doses but one of AQB-565 in the same range suppressed spasms in P15 rats (treatment stopped on P14). 30875634 2019